{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Naloxone : Questions médicales les plus fréquentes",
"headline": "Naloxone : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Naloxone : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-09",
"dateModified": "2025-02-03",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Naloxone"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Morphinanes",
"url": "https://questionsmedicales.fr/mesh/D009019",
"about": {
"@type": "MedicalCondition",
"name": "Morphinanes",
"code": {
"@type": "MedicalCode",
"code": "D009019",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.723.795"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Naltrexone",
"alternateName": "Naltrexone",
"url": "https://questionsmedicales.fr/mesh/D009271",
"about": {
"@type": "MedicalCondition",
"name": "Naltrexone",
"code": {
"@type": "MedicalCode",
"code": "D009271",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.723.795.706.550"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Naloxone",
"alternateName": "Naloxone",
"code": {
"@type": "MedicalCode",
"code": "D009270",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Alexander Y Walley",
"url": "https://questionsmedicales.fr/author/Alexander%20Y%20Walley",
"affiliation": {
"@type": "Organization",
"name": "Boston Medical Center and Boston University School of Medicine, Grayken Center for Addiction, Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, 801 Massachusetts Ave, 2nd Floor, Boston, MA 02118, USA."
}
},
{
"@type": "Person",
"name": "Traci C Green",
"url": "https://questionsmedicales.fr/author/Traci%20C%20Green",
"affiliation": {
"@type": "Organization",
"name": "The Heller School for Social Policy and Management at Brandeis University, Institute for Behavioral Health, 415 South St, MS 035, Waltham, MA 02453, USA."
}
},
{
"@type": "Person",
"name": "Lucas G Hill",
"url": "https://questionsmedicales.fr/author/Lucas%20G%20Hill",
"affiliation": {
"@type": "Organization",
"name": "College of Pharmacy, The University of Texas at Austin, Austin, TX, USA."
}
},
{
"@type": "Person",
"name": "Kirk E Evoy",
"url": "https://questionsmedicales.fr/author/Kirk%20E%20Evoy",
"affiliation": {
"@type": "Organization",
"name": "College of Pharmacy, The University of Texas at Austin, Austin, TX, USA."
}
},
{
"@type": "Person",
"name": "John Strang",
"url": "https://questionsmedicales.fr/author/John%20Strang",
"affiliation": {
"@type": "Organization",
"name": "National Addiction Centre, Institute of Psychiatry Psychology and Neuroscience, King's College London, London, SE5 8BB, UK."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Naloxone training and availability in the US commercial fishing industry.",
"datePublished": "2023-05-30",
"url": "https://questionsmedicales.fr/article/37249103",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/ajim.23491"
}
},
{
"@type": "ScholarlyArticle",
"name": "Association Between Naloxone Coprescription Mandates and Postoperative Outcomes.",
"datePublished": "2023-02-20",
"url": "https://questionsmedicales.fr/article/36805578",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/SLA.0000000000005821"
}
},
{
"@type": "ScholarlyArticle",
"name": "First Responders' Views of Naloxone: Does Stigma Matter?",
"datePublished": "2022-07-06",
"url": "https://questionsmedicales.fr/article/35791871",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/10826084.2022.2092150"
}
},
{
"@type": "ScholarlyArticle",
"name": "Disparities in opioid overdose survival and naloxone administration in Pennsylvania.",
"datePublished": "2022-07-04",
"url": "https://questionsmedicales.fr/article/35810621",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.drugalcdep.2022.109555"
}
},
{
"@type": "ScholarlyArticle",
"name": "Who is using take-home naloxone? An examination of supersavers.",
"datePublished": "2022-06-18",
"url": "https://questionsmedicales.fr/article/35717240",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12954-022-00647-z"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés polycycliques",
"item": "https://questionsmedicales.fr/mesh/D011083"
},
{
"@type": "ListItem",
"position": 3,
"name": "Hydrocarbures aromatiques polycycliques",
"item": "https://questionsmedicales.fr/mesh/D011084"
},
{
"@type": "ListItem",
"position": 4,
"name": "Phénanthrènes",
"item": "https://questionsmedicales.fr/mesh/D010616"
},
{
"@type": "ListItem",
"position": 5,
"name": "Morphinanes",
"item": "https://questionsmedicales.fr/mesh/D009019"
},
{
"@type": "ListItem",
"position": 6,
"name": "Naloxone",
"item": "https://questionsmedicales.fr/mesh/D009270"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Naloxone - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Naloxone",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-04-29",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Naloxone",
"description": "Comment diagnostiquer une surdose d'opioïdes ?\nQuels tests sont utilisés pour confirmer une surdose ?\nQuels signes indiquent une surdose d'opioïdes ?\nQuand utiliser la naloxone en cas de surdose ?\nLa naloxone est-elle efficace pour tous les opioïdes ?",
"url": "https://questionsmedicales.fr/mesh/D009270?page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Naloxone",
"description": "Quels sont les symptômes d'une surdose d'opioïdes ?\nComment reconnaître une dépression respiratoire ?\nQuels sont les effets secondaires de la naloxone ?\nLa naloxone provoque-t-elle des effets immédiats ?\nQuels signes indiquent que la naloxone fonctionne ?",
"url": "https://questionsmedicales.fr/mesh/D009270?page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Naloxone",
"description": "Comment prévenir les surdoses d'opioïdes ?\nLa naloxone est-elle disponible sans ordonnance ?\nQuels programmes aident à prévenir les surdoses ?\nComment sensibiliser à l'utilisation de la naloxone ?\nLes proches doivent-ils avoir de la naloxone ?",
"url": "https://questionsmedicales.fr/mesh/D009270?page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Naloxone",
"description": "Comment administrer la naloxone ?\nQuelle est la posologie recommandée de naloxone ?\nLa naloxone peut-elle être administrée par des non-professionnels ?\nCombien de temps dure l'effet de la naloxone ?\nQue faire après l'administration de naloxone ?",
"url": "https://questionsmedicales.fr/mesh/D009270?page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Naloxone",
"description": "Quelles complications peuvent survenir après une surdose ?\nLa naloxone peut-elle causer des complications ?\nQuels sont les risques d'une surdose répétée ?\nComment gérer les complications post-surdose ?\nLes complications de la naloxone sont-elles fréquentes ?",
"url": "https://questionsmedicales.fr/mesh/D009270?page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Naloxone",
"description": "Quels sont les facteurs de risque de surdose d'opioïdes ?\nL'âge influence-t-il le risque de surdose ?\nLes antécédents familiaux jouent-ils un rôle ?\nL'utilisation de plusieurs substances augmente-t-elle le risque ?\nLes problèmes de santé mentale sont-ils un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D009270?page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une surdose d'opioïdes ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic repose sur des signes cliniques comme la dépression respiratoire et la confusion."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour confirmer une surdose ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins peuvent mesurer les niveaux d'opioïdes, mais l'évaluation clinique est primordiale."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une surdose d'opioïdes ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent somnolence extrême, respiration lente et pupilles constrictes."
}
},
{
"@type": "Question",
"name": "Quand utiliser la naloxone en cas de surdose ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "La naloxone doit être administrée dès que des signes de surdose sont observés."
}
},
{
"@type": "Question",
"name": "La naloxone est-elle efficace pour tous les opioïdes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est efficace pour la plupart des opioïdes, mais moins pour certains comme le fentanyl."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une surdose d'opioïdes ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent somnolence, confusion, respiration ralentie et perte de conscience."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une dépression respiratoire ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une respiration lente, superficielle ou absente est un signe de dépression respiratoire."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires de la naloxone ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des symptômes de sevrage chez les utilisateurs d'opioïdes."
}
},
{
"@type": "Question",
"name": "La naloxone provoque-t-elle des effets immédiats ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la naloxone agit rapidement, souvent en quelques minutes après l'administration."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent que la naloxone fonctionne ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une amélioration de la respiration et de la conscience indique que la naloxone est efficace."
}
},
{
"@type": "Question",
"name": "Comment prévenir les surdoses d'opioïdes ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éduquer sur l'utilisation sécuritaire des opioïdes et fournir des alternatives non opioïdes."
}
},
{
"@type": "Question",
"name": "La naloxone est-elle disponible sans ordonnance ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la naloxone est souvent disponible sans ordonnance dans de nombreux pays."
}
},
{
"@type": "Question",
"name": "Quels programmes aident à prévenir les surdoses ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des programmes de distribution de naloxone et d'éducation sur les opioïdes existent."
}
},
{
"@type": "Question",
"name": "Comment sensibiliser à l'utilisation de la naloxone ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des campagnes d'information et des formations sur la naloxone peuvent sensibiliser le public."
}
},
{
"@type": "Question",
"name": "Les proches doivent-ils avoir de la naloxone ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, avoir de la naloxone à portée de main peut sauver des vies en cas de surdose."
}
},
{
"@type": "Question",
"name": "Comment administrer la naloxone ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "La naloxone peut être administrée par injection intramusculaire ou par spray nasal."
}
},
{
"@type": "Question",
"name": "Quelle est la posologie recommandée de naloxone ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La dose initiale est généralement de 0,4 à 2 mg, répétée toutes les 2-3 minutes si nécessaire."
}
},
{
"@type": "Question",
"name": "La naloxone peut-elle être administrée par des non-professionnels ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la naloxone peut être administrée par des témoins ou des proches en cas d'urgence."
}
},
{
"@type": "Question",
"name": "Combien de temps dure l'effet de la naloxone ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'effet de la naloxone dure généralement de 30 à 90 minutes, nécessitant une surveillance."
}
},
{
"@type": "Question",
"name": "Que faire après l'administration de naloxone ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Après administration, il est crucial d'appeler les services d'urgence pour une évaluation."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir après une surdose ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des lésions cérébrales dues à l'hypoxie et des problèmes respiratoires."
}
},
{
"@type": "Question",
"name": "La naloxone peut-elle causer des complications ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications peuvent survenir, notamment des symptômes de sevrage chez les utilisateurs d'opioïdes."
}
},
{
"@type": "Question",
"name": "Quels sont les risques d'une surdose répétée ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les surdoses répétées augmentent le risque de dommages permanents et de décès."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications post-surdose ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une prise en charge médicale rapide est essentielle pour traiter les complications post-surdose."
}
},
{
"@type": "Question",
"name": "Les complications de la naloxone sont-elles fréquentes ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications sont rares, mais peuvent survenir, surtout chez les utilisateurs réguliers d'opioïdes."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque de surdose d'opioïdes ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'utilisation d'opioïdes, l'usage de mélanges de drogues et des antécédents de dépendance."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de surdose ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les jeunes adultes et les personnes âgées sont souvent à risque accru de surdose."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un historique familial de dépendance peut augmenter le risque de surdose."
}
},
{
"@type": "Question",
"name": "L'utilisation de plusieurs substances augmente-t-elle le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le mélange d'opioïdes avec d'autres dépresseurs du système nerveux central augmente le risque."
}
},
{
"@type": "Question",
"name": "Les problèmes de santé mentale sont-ils un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les troubles de santé mentale peuvent augmenter le risque de dépendance et de surdose."
}
}
]
}
]
}
Workers in physically demanding jobs with high injury rates, long hours, productivity pressures, and lack of job security, such as commercial fishing, are at higher risk for substance use and misuse. ...
As part of a larger study of commercial fishing vessel captains, we asked participants how worried they are about various potential problems, including substance use by crew members, using a five-poin...
Of the 61 vessel captains who participated, 10 had naloxone training. Most were "not at all worried" about a crew member misusing alcohol (n = 52; 85.2%), a crew member using marijuana (n = 50; 82.0%)...
Our results indicate that few fishing vessels are equipped with naloxone or have captains trained in its use. Fishing captains tend not to be worried about substance use in their crew. Given the highe...
The opioid epidemic is a public health issue in the United States. The objective of this study was to evaluate the association between naloxone coprescription mandates and postoperative outcomes....
Data on naloxone coprescription mandates show mixed evidence for fatal overdoses in the broader population. How these mandates have impacted surgical patients has not been fully explored....
Healthcare claims data were used to identify all patients undergoing 1 of 50 common procedures between January 1, 2004, and June 30, 2019, and categorized as high risk for opioid overdose. The primary...
The study included 429,878 surgical patients with an average age of 54.8 years (SD=15.9 years) and with 257,728 females (60.0%). There was no significant association between naloxone prescribing manda...
Naloxone coprescription mandates were not associated with a statistically or clinically significant change in emergency department visits or hospital admissions within 30 postoperative days....
Prior work has suggested that first responders have mixed feelings about harm reduction strategies used to fight the opioid epidemic, such as the use of naloxone to reverse opioid overdose. Researcher...
A web-based survey assessing perceptions of PWUO and naloxone was administered to 282 police officers and students enrolled in EMT and paramedic training courses located in the Northeastern United Sta...
Participants, in the aggregate, held slightly negative attitudes toward the use of naloxone. Findings from multivariable modeling suggest that stigma of OUD, living in a rural area, and prior experien...
Efforts to alleviate perceptions of PWUO as dangerous, blameworthy, or incapable of recovery may increase first responders' support for naloxone. To this end, first responder training programs should ...
Pennsylvania has one of the highest opioid overdose rates in the US; however, since 2018 approximately 80% of people who experienced an opioid overdose in the state survived. More attention has been p...
We use 2018-2020 Pennsylvania Overdose Information Network data on opioid incidents and where they occurred, combined with 2015-2019 American Community Survey data, to evaluate opioid overdose surviva...
Individuals who received at least one dose of naloxone following overdose had 11 times greater odds of survival. White, middle-aged men were least likely to survive opioid overdose. Both survival and ...
Expanding naloxone distribution and administration and ensuring proper education about standing orders for naloxone administration are important tools for addressing opioid overdose mortality....
As the opioid overdose crisis persists and take-home naloxone (THN) programmes expand, it is important that the intervention is targeted towards those most likely to use it. We examined THN program pa...
This study included a cohort of consenting THN recipients from June 2014-June 2021 who completed initial and refill questionnaires from a widespread program in Norway. Age, gender, number of witnessed...
A total of 1054 participants returned for a THN refill during the study period. Of these, 558 reported their last THN to have been used on an overdose. Supersavers (those that reported 3 or more THN u...
THN programs should continue to emphasize and prioritize THN for people actively using drugs, particularly those who have witnessed overdoses previously....
The opioid crisis remains a major public health concern in the United States. Naloxone is used to reverse opioid overdoses. This study examined Medicaid expansion on naloxone prescriptions in retail p...
We used population average models to evaluate the association of Medicaid expansion at the state level on the number of naloxone prescriptions dispensed and the percentage paid by Medicaid, including ...
States that expanded Medicaid had higher unadjusted naloxone dispensing rates and Medicaid-paid percentage of naloxone in metro and nonmetro areas. Medicaid expansion was not associated with the numbe...
Medicaid expansion increased naloxone access by increasing the Medicaid-paid percentage of naloxone prescriptions in metro areas. States with Medicaid expansion had a faster rate of increase in the Me...
The incidence of opioid-associated out-of-hospital cardiac arrest (OA-OHCA) has grown from less than 1% of OHCA in 2000 to between 7% and 14% of OHCA in recent years; American Heart Association (AHA) ...
To evaluate the association of naloxone with clinical outcomes in patients with undifferentiated OHCA....
Retrospective cohort study of EMS-treated patients aged 18 or older who received EMS treatment for nontraumatic OHCA in 3 Northern California counties between 2015 and 2023. Data were analyzed using p...
EMS administration of naloxone....
The primary outcome was survival to hospital discharge; the secondary outcome was sustained return of spontaneous circulation (ROSC). Covariates included patient and cardiac arrest characteristics (eg...
Among 8195 patients (median [IQR] age, 65 [51-78] years; 5540 male [67.6%]; 1304 Asian, Native Hawaiian, or Pacific Islander [15.9%]; 1119 Black [13.7%]; 2538 White [31.0%]) with OHCA treated by 5 EMS...
In this retrospective cohort study, naloxone administration as part of EMS management of OHCA was associated with increased rates of ROSC and increased survival to hospital discharge when evaluated us...
Naloxone is a life-saving medication for individuals experiencing an opioid overdose. Naloxone standing orders aim to make naloxone more available by allowing patients improved access to this medicati...
To characterize naloxone availability and out-of-pocket cost under the state standing order in Mississippi....
This telephone-based, mystery-shopper census survey study included Mississippi community pharmacies open to the general public in Mississippi at the time of data collection. Community pharmacies were ...
Mississippi House bill 996, the Naloxone Standing Order Act, signed into law in 2017, allowing pharmacists to dispense naloxone under a physician state standing order at a patient's request....
The main outcomes were naloxone availability under Mississippi's state standing order and the out-of-pocket cost of available formulations....
There were 591 open-door community pharmacies surveyed for this study, with a 100% response rate. The most common pharmacy type was independent (328 [55.50%]), followed by chain (147 [24.87%]) and gro...
In this survey study of open-door Mississippi community pharmacies, availability of naloxone was limited despite standing order implementation. This finding has important implications for the effectiv...
Since the COVID-19 pandemic, an increase in fentanyl-combined drugs has led to a surge in opioid overdose deaths in the United States. Higher opioid overdose mortality rates are problematic in rural c...
This exploratory project aimed to investigate a hands-on naloxone training for rural clinicians and staff. Rural clinicians and staff at two behavioral health centers were recruited to participate in ...
Of the nine participants in the project, seven (87.5%) were female and six (75.0%) were Black. Four participants assumed a therapist role, attained a MS or MA degree, and had 5 or more years of experi...
A hands-on naloxone training is beneficial for training rural clinicians and staff to respond to opioid overdose. This training may be a promising solution to reduce response time between recognition ...
This innovative hands-on naloxone training is designed for rural clinicians and residents who are most likely to witness individuals experiencing opioid toxicity. The primary goal is to reduce respons...
Emergency departments (EDs) are important venues for the distribution of naloxone to patients at high risk of opioid overdose, but less is known about patient perceptions on naloxone or best practices...
We conducted semi-structured telephone interviews with 25 adult participants seen and discharged from three urban, academic EDs in Philadelphia, PA, with a naloxone prescription between November 2020 ...
Of the 25 participants, 72% had previously witnessed an overdose and 48% had personally experienced a non-fatal overdose. Nineteen participants (76%) self-disclosed a history of substance use or overd...
Naloxone prescribing in the ED was acceptable and valued by most participants, but there are missed opportunities for communication and education. These findings underscore the critical role that EDs ...
